A newly developed prediction model may be able to calculate the risk of opioid relapse among individuals in the early stages of medication treatment-;as early as three weeks into therapy.
In drug development, diversity must be extended to preclinical research
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This
August 22, 2024